Alzamend Neuro - Corporate Logo Bar and Head w TM Only 01032017.jpg
New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
October 27, 2020 06:56 ET | Alzamend Neuro, Inc.
TAMPA, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association....